Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

NEW YORK – The US Food and Drug Administration announced Thursday that Cepheid's test for SARS-CoV-2, influenza, and respiratory syncytial virus received Emergency Use Authorization for use in high and moderate complexity laboratories and at the point of care. 

The rapid multiplex RT-PCR test detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus RNA and can provide results in 35 minutes. 

The test runs on the company's GeneXpert Dx and GeneXpert Infinity instruments in CLIA-certified moderate and high complexity labs and is indicated for use with nasopharyngeal and nasal swabs and nasal wash/aspirate specimens. The Xpert Xpress SARS-CoV-2/Flu/RSV test runs on the GeneXpert Xpress System at the point of care and is authorized for nasopharyngeal and nasal swabs in CLIA-waived settings.

The Danaher subsidiary announced plans to launch the multiplex test during its second quarter earnings call in July. Cepheid was the first company to receive EUA for a point-of-care test for SARS-CoV-2 in March.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.